148 related articles for article (PubMed ID: 24559182)
1. Association of alpha2a and beta2 adrenoceptor expression with clinical outcome in breast cancer.
Du Y; Zhou L; Wang Y; Yan T; Jiang Y; Shao Z; Yin W; Lu J
Curr Med Res Opin; 2014 Jul; 30(7):1337-44. PubMed ID: 24559182
[TBL] [Abstract][Full Text] [Related]
2. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
3. Re: association of alpha2a and beta2 adrenoceptor expression with clinical outcome in breast cancer.
Patanè S
Curr Med Res Opin; 2015 Feb; 31(2):333-4. PubMed ID: 24968141
[No Abstract] [Full Text] [Related]
4. Prognostic significance of α- and β2-adrenoceptor gene expression in breast cancer patients.
Rivero EM; Martinez LM; Bruque CD; Gargiulo L; Bruzzone A; Lüthy IA
Br J Clin Pharmacol; 2019 Sep; 85(9):2143-2154. PubMed ID: 31218733
[TBL] [Abstract][Full Text] [Related]
5. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
[TBL] [Abstract][Full Text] [Related]
6. The presence of beta2-adrenoceptors sensitizes alpha2A-adrenoceptors to desensitization after chronic epinephrine treatment.
Bawa-Khalfe T; Altememi GF; Mandyam CD; Schwarz LA; Eikenburg DC; Standifer KM
BMC Pharmacol; 2007 Dec; 7():16. PubMed ID: 18096057
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of β2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma.
Takahashi K; Kaira K; Shimizu A; Sato T; Takahashi N; Ogawa H; Yoshinari D; Yokobori T; Asao T; Takeyoshi I; Oyama T
Tumour Biol; 2016 Oct; 37(10):13885-13892. PubMed ID: 27485115
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma.
Bravo-Calderón DM; Oliveira DT; Marana AN; Nonogaki S; Carvalho AL; Kowalski LP
Cancer Biomark; 2011-2012; 10(1):51-9. PubMed ID: 22297552
[TBL] [Abstract][Full Text] [Related]
11. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.
Qin T; Zeng YD; Qin G; Xu F; Lu JB; Fang WF; Xue C; Zhan JH; Zhang XK; Zheng QF; Peng RJ; Yuan ZY; Zhang L; Wang SS
Oncotarget; 2015 Oct; 6(32):33972-81. PubMed ID: 26378017
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
13. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
14. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
[TBL] [Abstract][Full Text] [Related]
15. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
18. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis.
Tong ZJ; Shi NY; Zhang ZJ; Yuan XD; Hong XM
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28667103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
